A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases

被引：0
|
作者：
Rugo, H. [1 ]
Petrenciuc, O. [2 ]
Zhang, A. [3 ]
Li, R. [4 ]
Coleman, R. E. [5 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[2] Pharmaceut Div Bayer, Global Clin Dev, Whippany, NJ USA
[3] Pharmaceut Div Bayer, Global Dev, Whippany, NJ USA
[4] Pharmaceut Div Bayer, Global Res & Dev Stat, Whippany, NJ USA
[5] Univ Sheffield, Weston Pk Hosp, Oncol, Sheffield, S Yorkshire, England
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw365.89
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
310TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Rozenblit, Mariya
    Mun, Sophia
    Soulos, Pamela
    Adelson, Kerin
    Pusztai, Lajos
    Mougalian, Sarah
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [22] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [23] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Mariya Rozenblit
    Sophia Mun
    Pamela Soulos
    Kerin Adelson
    Lajos Pusztai
    Sarah Mougalian
    Breast Cancer Research, 23
  • [24] Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2
    Pritchard, Kathleen I.
    Burris, Howard A., III
    Ito, Yoshinori
    Rugo, Hope S.
    Dakhil, Shaker
    Hortobagyi, Gabriel N.
    Campone, Mario
    Csoszi, Tibor
    Baselga, Jose
    Puttawibul, Puttisak
    Piccart, Martine
    Heng, Daniel
    Noguchi, Shinzaburo
    Srimuninnimit, Vichien
    Bourgeois, Hugues
    Gonzalez Martin, Antonio
    Osborne, Karen
    Panneerselvam, Ashok
    Taran, Tetiana
    Sahmoud, Tarek
    Gnant, Michael
    CLINICAL BREAST CANCER, 2013, 13 (06) : 421 - U113
  • [25] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Sohita Dhillon
    Drugs, 2013, 73 : 475 - 485
  • [26] Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II study
    Rugo, H. S.
    Drumea, K.
    Lee, S. C.
    Campone, M.
    Van Poznak, C.
    Neven, P.
    Alonso, E. Vega
    Naume, B.
    Siegel, J. M.
    Li, R.
    Uema, D.
    Wagner, V. J.
    Coleman, R. E.
    ANNALS OF ONCOLOGY, 2022, 33 : S211 - S212
  • [27] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Dhillon, Sohita
    DRUGS, 2013, 73 (05) : 475 - 485
  • [28] Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
    Oliveira, Mafalda
    Rugo, Hope S.
    Howell, Sacha J.
    Dalenc, Florence
    Cortes, Javier
    Gomez, Henry L.
    Hu, Xichun
    Toi, Masakazu
    Jhaveri, Komal
    Krivorotko, Petr
    Loibl, Sibylle
    Murillo, Serafin Morales
    Okera, Meena
    Nowecki, Zbigniew
    Park, Yeon Hee
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Yousef, Samih
    Zhukova, Lyudmila
    Fulford, Marta
    Andrews, Haylee
    Wadsworth, Ian
    D'Cruz, Celina
    Turner, Nicholas C.
    LANCET ONCOLOGY, 2024, 25 (09): : 1231 - 1244
  • [29] Immunotherapy for hormone receptor-positive HER2-negative breast cancer
    Cardoso, Fatima
    Hirshfield, Kim M.
    Kraynyak, Kimberly A.
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NPJ BREAST CANCER, 2024, 10 (01)
  • [30] A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer
    Yardley, Denise A.
    Awada, Ahmad
    Cortes, Javier
    Burris, Howard A.
    Peterson, Amy C.
    Tudor, Iulia Cristina
    Stopatschinskaja, Shanna
    Steinberg, Joyce Leta
    Gianni, Luca
    Miller, Kathy D.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345